Compare Futu Holdings Ltd (FUTU) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Eli Lilly And Co — how do they compare? Futu Holdings Ltd trades at $98.2 (market cap $13.94B), while Eli Lilly And Co trades at $1,175.14 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 73.9× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays the higher dividend (2.62%). Which is the better fit depends on your goals.
| FUTU | LLY | |
|---|---|---|
Market Cap | $13.94B | $1.03T |
Sector | Financials | Health |
52-Week High | $199.04 | $1.24K |
52-Week Low | $89.76 | $625.65 |
Enterprise Value | $13.79B | $1.07T |
Dividend Yield | 2.62% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUTU Holdings trades at $98.13, up 1.85% with a bullish technical signal despite mixed earnings. The company shows strong fundamentals with 2025 revenue of $22.85B and net income of $11.34B, supported by robust profitability margins. However, recent quarterly earnings misses and ongoing securities class action lawsuits create significant headwinds.
While valuation metrics appear reasonable with P/E of 10.98 and analyst consensus leaning bullish (58% buy ratings), investors face substantial legal and regulatory risks. The stock's near-term trajectory will depend on Q2 2026 earnings results and resolution of multiple class action lawsuits alleging securities fraud violations.
LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.
Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
